Table 1. Patient and clinical characteristics.
Characteristics | Group 1 (n=216) | Group 2 (n=219) | p | |
---|---|---|---|---|
Age (yr) | 56 (22–83) | 55 (26–79) | 0.779 | |
BMI (kg/m2) | 22.9 (16.0–40.3) | 22.5 (16.4–34.4) | 0.530 | |
FIGO stage | <0.001 | |||
III | 152 (70.4) | 93 (42.5) | ||
IV | 64 (29.6) | 126 (57.5) | ||
Tumor grade | 0.214 | |||
1 | 16 (7.4) | 11 (5.0) | ||
2 | 72 (33.4) | 62 (28.3) | ||
3 | 107 (49.5) | 113 (51.6) | ||
Not available | 21 (9.7) | 33 (15.1) | ||
Histologic type | 0.696 | |||
Serous | 174 (80.6) | 179 (82.1) | ||
Endometrioid | 10 (4.6) | 5 (2.3) | ||
Mucinous | 14 (6.5) | 14 (6.4) | ||
Clear cell | 9 (4.2) | 12 (5.5) | ||
Other | 9 (4.2) | 9 (3.7) | ||
ASA score | <0.001 | |||
1 | 128 (59.3) | 60 (27.4) | ||
2 | 77 (35.6) | 110 (50.2) | ||
3 | 5 (2.3) | 42 (19.2) | ||
4 | 0 (0) | 1 (0.5) | ||
Not available | 6 (2.8) | 6 (2.7) | ||
Median CA-125 level (U/mL) | 897.1 (8.7–30,008.8) | 1,474.1 (12.9–30,000.0) | 0.003 | |
NAC | <0.001 | |||
Yes | 35 (16.2) | 107 (48.9) | ||
No | 181 (83.8) | 112 (51.1) | ||
Chemotherapy regimen | 0.006 | |||
Paclitaxel+carboplatin | 156 (72.2) | 171 (78.1) | ||
Docetaxel+carboplatin | 25 (11.6) | 36 (16.4) | ||
Paclitaxel+carboplatin+bevacizumab | 1 (0.5) | 3 (1.4) | ||
Paclitaxel+cisplatin | 2 (0.9) | 3 (1.4) | ||
IP chemotherapy | 28 (13.0) | 0 (0) | ||
Others | 2 (0.9) | 2 (0.9) | ||
Not available | 2 (0.9) | 4 (1.8) | ||
Cycles of total chemotherapy | 0.005 | |||
≤6 | 158 (73.1) | 132 (60.3) | ||
>6 | 58 (26.9) | 87 (39.7) |
Values are presented as median (range) or number (%).
ASA, American Society of Anesthesiologists; BMI, body mass index; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; IP, intraperitoneal; NAC, neoadjuvant chemotherapy.